By Fineline Cube Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory study for LM-108, a CCR8-targeted monoclonal antibody (mAb) co-developed by its subsidiary LaNova Medicines following their strategic deal in November 2024. The trial will evaluate LM-108 in combination with a PD-1 inhibitor for second-line treatment of CCR8-positive locally advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Development Milestone
| Item | Detail |
|---|---|
| Developer | Sino Biopharmaceutical Ltd. (HKG: 1177) / LaNova Medicines (subsidiary) |
| Study Phase | Phase III regulatory trial initiated |
| Product | LM-108 (CCR8-targeted monoclonal antibody) |
| Combination Partner | PD-1 inhibitor |
| Indication | Second-line CCR8-positive locally advanced or metastatic G/GEJ adenocarcinoma |
| Milestone Date | First patient enrolled – 7 May 2026 |
Regulatory Recognition & Prior Designations
Breakthrough Therapy Designations (BTDs)
- MSI-H/dMMR Advanced Solid Tumors: LM-108 + toripalimab for patients who progressed following prior immune checkpoint inhibitor therapy
- CCR8-Positive Advanced G/GEJ Adenocarcinoma: LM-108 + toripalimab for patients who failed first-line standard therapy
These dual Breakthrough Therapy Designations from Chinese regulatory authorities highlight the significant unmet medical need and promising early clinical data supporting LM-108’s development across multiple tumor types.
Clinical Strategy & Innovation
| Aspect | Details |
|---|---|
| Target | CCR8 (C-C chemokine receptor type 8) – expressed on immunosuppressive regulatory T cells (Tregs) in tumor microenvironment |
| Mechanism | Depletes tumor-infiltrating Tregs while sparing peripheral Tregs, potentially enhancing anti-tumor immunity without systemic autoimmunity |
| Combination Rationale | Synergistic effect with PD-1 inhibitors by simultaneously targeting complementary immune evasion pathways |
| Patient Selection | CCR8-positive tumors – biomarker-driven approach to identify patients most likely to benefit |
The Phase III trial represents a precision medicine strategy targeting a molecularly defined patient population with high unmet need in gastric cancer, one of China’s most prevalent malignancies.
Market Context & Strategic Implications
- Gastric Cancer Burden: China accounts for approximately 40% of global gastric cancer cases, creating substantial demand for effective second-line therapies.
- Immunotherapy Evolution: The combination of novel immune targets (CCR8) with established checkpoint inhibitors (PD-1) represents the next frontier in immuno-oncology beyond monotherapy approaches.
- Subsidiary Integration: The successful advancement of LM-108 validates Sino Biopharmaceutical’s November 2024 acquisition of LaNova Medicines and demonstrates effective pipeline integration.
- Competitive Positioning: As one of the first CCR8-targeted antibodies to reach Phase III globally, LM-108 could establish first-mover advantage in this emerging therapeutic class.
The initiation of this pivotal trial positions Sino Biopharmaceutical to potentially deliver a transformative treatment option for gastric cancer patients with limited therapeutic alternatives in the second-line setting.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory designations, and market opportunities for LM-108. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech